Update (July 2014): I began an executive MBA program at St. Mary’s College in 2007 and finished in early 2009. Several personal genomics companies (deCode Genomics, 23andMe, Navigenics) came of age during this period, and I was fascinated by the idea of the $1000 genome. I completed this research just before the publication of Kevin Davies’ book, which covers the early development of these companies in much greater detail.

The Impact of the $1000 Genome: Personalized Medicine